This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Rebecca Voelker

JAMA. 2001;285:156.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A European-US collaboration has produced a new platinum-based drug that may hold promise for patients with difficult-to-treat ovarian cancer.

The new drug, code-named BBR3464, belongs to a new class of platinum drugs in which the molecular structure has been manipulated to attack cancer cells' DNA more aggressively to prevent tumor growth and metastasis. It is the result of joint studies by researchers at Novuspharma SpA (formerly Boehringer Mannheim Italia R&D) in Monza, Italy, and Virginia Commonwealth University. Preliminary data on the drug were presented last month during the International Chemical Congress of Pacific Basin Societies in Honolulu. The meeting is sponsored by the American Chemical Society and its counterparts in Australia, Canada, Japan, and New Zealand.

In phase 1 studies of 47 patients with cancer conducted in Europe, the drug showed activity against melanoma and pancreatic and lung cancers. Phase 2 studies that include a trial specifically examining . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

AIDS and Antiretroviral Drugs in South Africa: Public Health, Politics, and Individual Suffering: A Review of Brian Tilley's It's My Life
Noah
J Law Med Ethics 2003;31:144-148.